Skip to content
  • Sunday, 26 July 2026
  • 9:55 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Revolution Medicines’ Daraxonrasib Achieves Landmark Survival Extension in Pancreatic Cancer, Heralding New Era of Targeted Therapy
Pharmaceutical R&D

Revolution Medicines’ Daraxonrasib Achieves Landmark Survival Extension in Pancreatic Cancer, Heralding New Era of Targeted Therapy

Teuku Ryan Jun 2, 2026 0

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer. The 2026…

Read More
Pharmaceutical R&D

ASCO 2026: Lung Cancer Landscape Ignites with Promising Bispecifics, Targeted Therapies, and Extended Survival Data

Teuku Ryan Jun 1, 2026 0

The annual American Society of Clinical Oncology (ASCO) congress, a cornerstone event for the global oncology community, convened in Chicago,…

Read More
Pharmaceutical R&D

Eli Lilly and Company Secures Global Rights to Hanmi Pharm’s Sonefpeglutide in Potential $1.26 Billion Deal

Teuku Ryan Jun 1, 2026 0

Eli Lilly and Company has forged a significant licensing agreement with South Korean biopharmaceutical firm Hanmi Pharm, potentially worth up…

Read More
Pharmaceutical R&D

AbbVie Secures FDA Approval for Ultra-Rare Blood Cancer Therapy, While AstraZeneca Faces Delay for Breast Cancer Drug

Teuku Ryan May 31, 2026 0

The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…

Read More
Pharmaceutical R&D

The Dawn of Psychedelics in Medicine: Navigating the Path to Safe and Effective Implementation

Teuku Ryan May 30, 2026 0

The landscape of mental healthcare is on the cusp of a significant transformation with the burgeoning approval of psychedelic-assisted therapies.…

Read More
Pharmaceutical R&D

Sanofi’s Venglustat Receives Priority Review from US FDA for Type 3 Gaucher Disease

Teuku Ryan May 30, 2026 0

Sanofi has secured a significant milestone in its development of venglustat, an innovative oral glucosylceramide synthase inhibitor (GCSi), with the…

Read More
Pharmaceutical R&D

Pfizer and Innovent Biologics Announce Landmark Global Collaboration for Oncology Pipeline, Valued Up to $10.5 Billion

Teuku Ryan May 30, 2026 0

In a significant move poised to accelerate the development of novel cancer treatments, global pharmaceutical giant Pfizer and leading Chinese…

Read More
Pharmaceutical R&D

Radiopharmaceutical Logistics Navigates Perilous Path Amidst Rapid Market Growth

Teuku Ryan May 30, 2026 0

The burgeoning field of radiopharmaceutical therapies, once confined to niche applications, is rapidly ascending to become a mainstream pillar of…

Read More
Pharmaceutical R&D

NICE Recommends Nucala for Severe Asthma and COPD, Expanding Access to Advanced Biologic Therapy in the UK

Teuku Ryan May 29, 2026 0

In a significant development for respiratory healthcare in the United Kingdom, the National Institute for Health and Care Excellence (NICE)…

Read More
Pharmaceutical R&D

Scaling GLP-1 Obesity Trials Without Losing DXA Data

Teuku Ryan May 29, 2026 0

The explosive growth of global obesity trials, fueled by the success of GLP-1 receptor agonist therapies, presents a critical challenge:…

Read More

Posts pagination

1 … 9 10 11 … 32
University of Cambridge Study Reveals Shared Genetic Roots Between Golden Retriever Behavior and Human Emotional TraitsTop Automated Dispensing Cabinets for Pharmacies: Leading Brands ComparedTop 5 MCP Servers for High-Performance Agentic DevelopmentScience News: Empowering Public Understanding of Science, Medicine, and Technology Since 1921
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ